secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-06-04T11:16:36+00:00
Accession:  0001193125-26-256458
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax raises $250M via 2.25% convertible notes due 2031; conversion price at 35% premium
--------------------------------------------------------------------------------

- $250M aggregate principal, 2.25% interest, semiannual payments starting Dec 15, 2026, maturing June 15, 2031.
- Net proceeds ~$243M after fees; used for general corporate purposes including R&D, commercialization, and BD.
- Initial conversion rate 40.3894 shares per $1,000 principal, equivalent to ~$24.76/share (35% premium over June 3 closing).
- Notes are senior unsecured; callable only after June 20, 2029 if stock price exceeds 130% of conversion price.
- Conversion permitted upon certain stock price thresholds or specified corporate events; company may settle in cash, stock, or mix.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/0001193125-26-256458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/d65010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-256458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer